SABCS 2020 Clinical Roundup

News Articles

(OBR) Dec 11, 2020 - In patients with estrogen receptor (ER)-positive, HER2-negative breast cancer that is resistant to neoadjuvant endocrine therapy, the use of salvage neoadjuvant chemotherapy is not likely to induce a complete or near complete response, according to findings presented at the 2020 San Antonio Breast Cancer...
(OBR) Dec 11, 2020 - Pembrolizumab plus chemotherapy improved the progression-free survival, overall response rate, durable complete remission, and duration of response for patients with locally recurrent, unresectable or metastatic triple negative breast cancer (TNBC) with tumors expressing PD-L1 and a combined positive score (CPS) of...
(OBR) Dec 11, 2020 - An all-oral regimen of tesetaxel plus a reduced dose of capecitabine significantly improved progression-free survival (PFS) and other endpoints, compared with capecitabine alone, in patients with HER2-negative, hormone receptor (HR)-positive metastatic breast cancer (MBC), according to findings from the CONTESSA...
(OBR) Dec 10, 2020 - Omitting radiation after breast-conserving surgery may not impact 10-year survival rates in women 65 years or older with hormone receptor-positive, early invasive breast cancer, suggest long-term follow up results from the PRIME II trial. The findings were presented at the 2020 San Antonio Breast Cancer...
(OBR) Dec 10, 2020 - Women who undergo mastectomy and reconstruction surgery may face the risk of long-term dependence on opioids and sedative-hypnotic drugs, according to research presented at the 2020 San Antonio Breast Cancer Symposium. Around the time of breast cancer surgery, opioids are frequently prescribed for pain, and...
View all sabcs conference coverage news
OBR Blog
by Chase Doyle Day 4 of the 2020 San Antonio Breast Cancer Symposium (SABCS) virtual meeting featured advances in early... Read more
December 11, 2020
by Chase Doyle Day 3 of the 2020 San Antonio Breast Cancer Symposium (SABCS) virtual meeting featured advances in how... Read more
December 10, 2020
by Chase Doyle Cyclin-dependent kinase (CDK) inhibitors have improved survival of patients with hormone receptor... Read more
December 09, 2020